|
Cancer type
|
Characteristic
|
Total (cases)
|
HR (95% CI)
|
P
|
|---|
|
BRCA
|
Age (years)
|
|
≤ 60
|
96
|
1.000
| |
|
> 60
|
49
|
1.467 (0.864–2.752)
|
0.323
|
|
TNBCa
|
|
No
|
109
|
1.000
| |
|
Yes
|
24
|
2.296 (1.169–4.508)
|
0.016
|
|
TNM stageb
|
|
I/II
|
95
|
1.000
| |
|
III/IV
|
48
|
2.296 (1.279–4.120)
|
0.005
|
|
PGK1 pS203
|
|
Low
|
65
|
1.000
| |
|
High
|
80
|
1.905 (1.024–3.546)
|
0.042
|
|
PDHK1 pT338
|
|
Low
|
66
|
1.000
| |
|
High
|
79
|
1.969 (1.058–3.665)
|
0.032
|
|
LIHC
|
Age (years)
|
|
≤ 60
|
75
|
1.000
| |
|
> 60
|
110
|
1.351 (0.863–1.962)
|
0.527
|
|
Gender
|
|
Male
|
159
|
1.000
| |
|
Female
|
26
|
0.597 (0.327–1.087)
|
0.092
|
|
TNM stagec
|
|
I/II
|
73
|
1.000
| |
|
III/IV
|
104
|
2.796 (1.848–4.229)
|
< 0.001
|
|
PGK1 pS203
|
|
Low
|
107
|
1.000
| |
|
High
|
78
|
1.909 (1.311–2.781)
|
0.001
|
|
PDHK1 pT338
|
|
Low
|
105
|
1.000
| |
|
High
|
80
|
2.354 (1.610–3.441)
|
< 0.001
|
|
LUAD
|
Age (years)
|
|
≤ 60
|
84
|
1.000
| |
|
> 60
|
95
|
1.339 (0.944–1.900)
|
0.102
|
|
Gender
|
|
Male
|
104
|
1.000
| |
|
Female
|
75
|
0.775 (0.542–1.107)
|
0.162
|
|
TNM stage
|
|
I/II
|
105
|
1.000
| |
|
III/IV
|
74
|
1.861 (1.309–2.647)
|
0.001
|
|
PGK1 pS203
|
|
Low
|
74
|
1.000
| |
|
High
|
105
|
1.760 (1.221–2.537)
|
0.002
|
|
PDHK1 pT338
|
|
Low
|
75
|
1.000
| |
|
High
|
104
|
1.595 (1.111–2.291)
|
0.011
|
|
STAD
|
Age (years)
|
|
≤ 60
|
56
|
1.000
| |
|
> 60
|
39
|
1.754 (1.144–2.689)
|
0.010
|
|
Gender
|
|
Male
|
60
|
1.000
| |
|
Female
|
35
|
1.017 (0.660–1.567)
|
0.938
|
|
TNM staged
|
|
I/II
|
24
|
1.000
| |
|
III/IV
|
69
|
2.590 (1.536–4.365)
|
< 0.001
|
|
PGK1 pS203
|
|
Low
|
51
|
1.000
| |
|
High
|
44
|
1.797 (1.173–2.752)
|
0.007
|
|
PDHK1 pT338
|
|
Low
|
49
|
1.000
| |
|
High
|
46
|
1.694 (1.105–2.596)
|
0.016
|
|
ESCA
|
Age (years)
|
|
≤ 60
|
112
|
1.000
| |
|
> 60
|
102
|
1.869 (1.300–2.686)
|
0.001
|
|
Gender
|
|
Male
|
176
|
1.000
| |
|
Female
|
38
|
1.127 (0.709–1.789)
|
0.614
|
|
TNM stage
|
|
I/II
|
98
|
1.000
| |
|
III/IV
|
116
|
6.447 (4.139–10.043)
|
< 0.001
|
|
PGK1 pS203
|
|
Low
|
103
|
1.000
| |
|
High
|
111
|
1.669 (1.157–2.406)
|
0.006
|
|
PDHK1 pT338
|
|
Low
|
94
|
1.000
| |
|
High
|
120
|
1.763 (1.213–2.563)
|
0.003
|
- BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, HR hazard ratio, 95% CI 95% confidence interval, TNBC triple-negative breast cancer, PGK1 pS203 phosphorylated phosphoglycerate kinase 1 (PGK1) S203, PDHK1 pT338 phosphorylated phosphorylate pyruvate dehydrogenase kinase 1 (PDHK1) T338
- aThe data of TNBC in BRCA were available in 133 patients
- bThe data of TNM stage in BRCA were available in 143 patients
- cThe data of TNM stage in LIHC were available in 177 patients
- dThe data of TNM stage in STAD were available in 93 patients
